Practical guide for prescribing MAOIs: debunking myths and removing barriers

Grady, Meghan M.; Stahl, Stephen M.

doi:10.1017/s109285291200003x

Cited by 51Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesElectroconvulsive Therapy Studies

Practical guide for prescribing MAOIs: debunking myths and removing barriers

Grady, Meghan M., Stahl, Stephen M.·2012·CNS Spectrums

DOI 10.1017/s109285291200003x

Open this paper in CoChat — free account

Abstract

Despite the fact that monoamine oxidase inhibitors (MAOIs) can be highly effective therapeutic agents for depression and some anxiety disorders, they tend to be underutilized in clinical practice. This is due at least in part to the fact that there is a great deal of misinformation and mythology about their dietary and drug interactions. This article is intended to serve as a guide for clinicians who are not particularly familiar with MAO inhibitors; its aim is to help these clinicians competently integrate these agents into clinical practice when appropriate.

Integrity signals

Registry

Crossref · 10.1017/s109285291200003x

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Safety was a big concern with MAOIs because fatal hypertensive crises could occur if large amounts of tyramine was obtained from food.
“Safety was a big concern with MAOIs because fatal hypertensive crises could occur if large amounts of tyramine was obtained from food.”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [100]

The serotonin syndrome
Sternbach, H. A. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,349 · see citing works
The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity
Dunkley, E. J. C., Isbister, G. K., Sibbritt, D. W., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,032 · see citing works
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694 · see citing works
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman, P. K. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei210 · Cited by 399 · see citing works
A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 249 · see citing works
Stahl's Essential Psychopharmacology
Stahl, S. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009053365 · Cited by 212 · see citing works
Self-citation
Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data
Lawrence, K. R., Adra, M., & Gillman, P. K. (2006) · Clinical Infectious Diseases · doi:10.1086/503839 · Cited by 203 · see citing works
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Prada, M. D., Kettler, R., Keller, H. H., Burkard, W. P., Muggli-Maniglio, D., & Haefely, W. E. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23665-5 · Cited by 199 · see citing works
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
Prada, M. D., Zürcher, G., Wüthrich, I., & Haefely, W. E. (1988) · PubMed · Cited by 176 · see citing works
Drug-induced serotonin syndrome: a review
Sun‐Edelstein, C., Tepper, S. J., & Shapiro, R. E. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.5.587 · Cited by 167 · see citing works
Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression
Lotufo-Neto, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00075-x · Cited by 159 · see citing works
A Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Selegiline Transdermal System Without Dietary Restrictions in Patients With Major Depressive Disorder
Amsterdam, J. D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0216 · Cited by 147 · see citing works
A Spontaneous Point Mutation Produces Monoamine Oxidase A/B Knock-out Mice with Greatly Elevated Monoamines and Anxiety-like Behavior*♦
Chen, K., Holschneider, D., Wu, W., Rebrin, I., & Shih, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405550200 · Cited by 144 · see citing works
Tapentadol in Pain Management
Hartrick, C. T., & Rozek, R. J. (2011) · CNS Drugs · doi:10.2165/11589080-000000000-00000 · Cited by 126 · see citing works
Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery
Huyse, F. J., Touw, D. J., van Schijndel, R. J. M. S., de Lange, J. J., & Slaets, J. P. J. (2005) · Psychosomatics · doi:10.1176/appi.psy.47.1.8 · Cited by 123 · see citing works
CNS Stimulant Potentiation of Monoamine Oxidase
FAWCETT, J. A., Kravitz, H. M., Zajecka, J., SCHAFF, M. R., & FREISHTAT, H. W. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199104000-00010 · Cited by 118 · see citing works
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
Feighner, J. P., Herbstein, J., & Damlouji, N. F. (1985) · PubMed · Cited by 104 · see citing works
MAO inhibitors: Risks, benefits, and lore
Wimbiscus, M. M., Kostenko, O., & Malone, D. A. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09103 · Cited by 101 · see citing works
The making of a user friendly MAOI diet.
Gardner, D. M., Shulman, K. I., Walker, S., & Tailor, S. A. N. (1996) · PubMed · Cited by 95 · see citing works
Selegiline Transdermal System for the Treatment of Major Depressive Disorder
Feiger, A. D., Rickels, K., Rynn, M. A., ZIMBROFF, D. L., & Robinson, D. S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0905 · Cited by 88 · see citing works
Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?
Mendis, N., Pare, C. M. B., Sandler, M., Glover, V. A. S., & Stern, G. M. (1981) · Psychopharmacology · doi:10.1007/bf00431109 · Cited by 87 · see citing works
Refining the MAOI Diet
Shulman, K. I., & Walker, S. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0308 · Cited by 87 · see citing works
Revisiting monoamine oxidase inhibitors.
Krishnan, K. R. R. (2007) · PubMed · Cited by 82 · see citing works
The long-term treatment of social phobia with moclobemide
Versiani, M., Nardi, A. E., Mundim, F. D., Pinto, S., Saboya, E., & Kovacs, R. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00014 · Cited by 79 · see citing works
Serotonin syndrome: a complex but easily avoidable condition
Dvir, Y., & Smallwood, P. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.09.007 · Cited by 74 · see citing works
Dietary Restriction, Tyramine, and the Use of Monoamine Oxidase Inhibitors
Shulman, K. I., Walker, S. E., MACKENZIE, S., & Sandra, K. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198912000-00002 · Cited by 69 · see citing works
Monoamine oxidase inhibitors: a review.
Gd, T. (1983) · PubMed · Cited by 67 · see citing works
A clinical overview of monoamine oxidase inhibitors
Zisook, S. (1985) · Psychosomatics · doi:10.1016/s0033-3182(85)72877-0 · Cited by 64 · see citing works
Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors.
Shulman, K. I., Walker, S., MACKENZIE, S., et al. (1989) · PubMed · Cited by 63 · see citing works
Moclobemide and Tricyclic Antidepressants in Severe Depression
Angst, J., Amrein, R., & Stabl, M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199508001-00004 · Cited by 57 · see citing works
Combining Stimulants With Monoamine Oxidase Inhibitors
Feinberg, S. S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1113 · Cited by 53 · see citing works
Refining the MAOI diet: tyramine content of pizzas and soy products.
Shulman, K. I., & Walker, S. (1999) · PubMed · Cited by 50 · see citing works
Transdermal selegiline: targeted effects on monoamine oxidases in the brain
Wecker, L., James, S., Copeland, N., & Pacheco, M. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01892-9 · Cited by 45 · see citing works
Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues
Mawhinney, M., Cole, D., & Azzaro, A. J. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2003.tb02430.x · Cited by 43 · see citing works
Recognition and Treatment of Panic Disorder
Lydiard, R. B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.1107e26 · Cited by 40 · see citing works
The Relative Efficacy of l-Deprenyl, a Selective Monoamine Oxidase Type B Inhibitor, in Endogenous and Nonendogenous Depression
Mann, J. J., FRANCES, A. J., Kaplan, R. D., Kocsis, J. H., Peselow, E. D., & Gershon, S. (1982) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198202000-00008 · Cited by 39 · see citing works
A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination
Berlanga, C., & Ortega-Soto, H. A. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00016-g · Cited by 36 · see citing works
Dietary consideration in MAO inhibitor regimens.
McCabe, B., & Tsuang, M. T. (1982) · PubMed · Cited by 35 · see citing works
Essential psychopharmacology: the prescriber's guide
Maj, M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00573.x · Cited by 34 · see citing works
Translating the Evidence on Atypical Depression Into Clinical Practice
Rapaport, M. H., & Thase, M. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0407e11 · Cited by 30 · see citing works
Similarity in the aldehyde oxidases from guinea-pig liver and polymorphonuclear leucocytes
Beedham, C. (1986) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1986.tb04468.x · Cited by 28 · see citing works
Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers
Azzaro, A. J., VanDenBerg, C. M., Ziemniak, J. A., Kemper, E. M., Blob, L. F., & Campbell, B. J. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302950 · Cited by 16 · see citing works
Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors
Rw, F. (1975) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(75)90203-3 · Cited by 13 · see citing works
A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors
Shulman, K. I., & Walker, S. E. (2001) · Psychiatric Annals · doi:10.3928/0048-5713-20010601-07 · Cited by 12 · see citing works
Pharmacokinetic studies of (—)-deprenyl and some of its metabolites in mouse
Magyar, K., Szatmáry, I., Szebeni, G., & Lengyel, J. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_21 · Cited by 11 · see citing works

Flagged first, then by citations

1 of the 46 references couldn’t be matched to a known paper.

Sorted by citations

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · see citing works
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224 · see citing works
Antidepressants- and antipsychotics-induced hepatotoxicity
Todorović, N., Đorđević, J., Pejić, S., Đorđević, N. O., & Pajović, S. B. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02963-4 · Cited by 119 · see citing works
Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression
Thomas, S. J., Shin, M., McInnis, M. G., & Bostwick, J. R. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1576 · Cited by 116 · see citing works
Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
Lum, C. T., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s1092852912000594 · Cited by 92 · see citing works
Self-citation
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability
Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77 · see citing works
Self-citation
Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
Edinoff, A. N., Swinford, C. R., Odisho, A. S., Burroughs, C. R., Stark, C. W., Raslan, W. A., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.39576 · Cited by 60 · see citing works
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
Chamberlain, S. R., & Baldwin, D. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00832-x · Cited by 50 · see citing works
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Entzeroth, M., & Ratty, A. K. (2017) · Open Journal of Depression · doi:10.4236/ojd.2017.62004 · Cited by 42 · see citing works
The therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36 · see citing works
Ketamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 36 · see citing works
Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure–Activity Relationships Predictive Models
Mladenović, M. P., Patsilinakos, A., Pirolli, A., Sabatino, M., & Ragno, R. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00608 · Cited by 35 · see citing works
A Qualitative Study of Intention and Impact of Ayahuasca Use by Westerners
Bathje, G. J., Fenton, J., Pillersdorf, D., & Hill, L. C. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211008331 · Cited by 34 · see citing works
Antidepressant discontinuation syndrome: A state-of-the-art clinical review
Fornaro, M., Cattaneo, C. I., Berardis, D. D., Ressico, F. V., Martinotti, G., & Vieta, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.005 · Cited by 29 · see citing works
Serotonin Syndrome
Cooper, B. E., & Sejnowski, C. A. (2013) · AACN Advanced Critical Care · doi:10.1097/nci.0b013e31827eecc6 · Cited by 25 · see citing works
Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression
Montano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 24 · see citing works
Antidepressant Drugs: Mechanisms of Action and Side Effects
Chang, J. P., Zamparelli, A., Nettis, M. A., & Pariante, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00105-5 · Cited by 22 · see citing works
The Effect of Saffron on Depression among Recovered Consumers of Methamphetamine Living with HIV/AIDS
Jalali, F., & Hashemi, S. F. (2018) · Substance Use & Misuse · doi:10.1080/10826084.2018.1447583 · Cited by 17 · see citing works
“Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
Gillman, P. K. (2017) · CNS Spectrums · doi:10.1017/s1092852916000651 · Cited by 15 · see citing works
Digital revolution in depression: A technologies update for clinicians
Lazar, M. A., Pan, Z., Ragguett, R.-M., Lee, Y., Subramaniapillai, M., Mansur, R. B., Rodrigues, N., & McIntyre, R. S. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.09.001 · Cited by 14 · see citing works
A critical appraisal of the selegiline transdermal system for major depressive disorder
Bied, A. M., Kim, J., & Schwartz, T. L. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1093416 · Cited by 14 · see citing works
Changes in Intensity of Serotonin Syndrome Caused by Adverse Interaction between Monoamine Oxidase Inhibitors and Serotonin Reuptake Blockers
Tao, R., Rudacille, M., Zhang, G., & Ma, Z. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.49 · Cited by 13 · see citing works
New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease
Kelberman, M. A., & Vazey, E. M. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0071-0 · Cited by 13 · see citing works
Movement Disorders
Julius, A., & Longfellow, K. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.002 · Cited by 11 · see citing works
The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors
den Eynde, V. V. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02399-9 · Cited by 8 · see citing works
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 7 · see citing works
Monoamino Oxidase Inhibitors Activities of Some Synthesized 2,6-bis (Tetracarboxamide)-pyridine and Macrocyclic Octacarboxamide Derivatives
Amr, A. E. E., Al-Omar, M. A., & Abdalla, M. M. (2016) · International Journal of Pharmacology · doi:10.3923/ijp.2016.66.73 · Cited by 6 · see citing works
Psychodiagnostic Classification Systems: A Critical View
Kountouras, G., & Sotirgiannidou, K. (2022) · International Journal of Social Science Research and Review · doi:10.47814/ijssrr.v5i4.226 · Cited by 5 · see citing works
Long-Term Adaptive Changes Induced by Antidepressants: From Conventional to Novel Therapies
Mnie‐Filali, O., Abrial, E., Lambás‐Señas, L., & Haddjeri, N. (2013) · InTech eBooks · doi:10.5772/54553 · Cited by 4 · see citing works
Neuroadaptations of the 5-HT System Induced by Antidepressant Treatments: Old and New Strategies
Haddjeri, N. (2014) · Addiction & Addictive Disorders · doi:10.24966/aad-7276/100001 · Cited by 3 · see citing works
Animal models for hepatoxicity
Singh, G., & Sharma, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90583-1.00007-6 · Cited by 3 · see citing works
Monoamine oxidase inhibitors for treatment-resistant depression
Bobo, W. V., & Richelson, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00009-8 · Cited by 3 · see citing works
Stratagems of Nanotechnology Augmenting the Bioavailability and Therapeutic Efficacy of Traditional Medicine to Formulate Smart Herbal Drugs Combating
Margret, A. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch052 · Cited by 3 · see citing works
Monoamine Oxidase Inhibitors in Depressive Disorders
Meyer, J. H., Matveychuk, D., Holt, A., Santhirakumar, A., & Baker, G. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_98 · Cited by 2 · see citing works
MAOI prescribing: separating misconceptions from reality
Molloy, A. (2023) · Prescriber · doi:10.1002/psb.2077 · Cited by 2 · see citing works
New Antidepressant Medication: Benefits Versus Adverse Effects
Bogdán, M., Gofiţă, E., Călina, D. C., Turcu-Ştiolică, A., Docea, A. O., Bălşeanu, T. A., Camen, A., Popa, E. G., Rusu, G., Cristofor, I., et al. (2018) · InTech eBooks · doi:10.5772/intechopen.72003 · Cited by 2 · see citing works
A Kinetic Study of Indentation Pop-out in Si
Wen, S. (2006) · Cited by 1 · see citing works
Depressive Störungen
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 1 · see citing works
Effect of Aqueous and Alcoholic Bee Pollen Extracts on Monoamine Oxidase Activity
Abbed, A. M., Shakir, M. A., Hussein, A. A., Abdulsada, S. H., Mohammed, L. F., & Lifatah, A. M. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00625 · Cited by 1 · see citing works
Appraising the neuroprotective competence of nitrogen-enriched Arthrospira platensis in comparison to commercial resource in depressed mice models
Margret, A. A., Kalaiyarasan, M., Jerley, A. A., & Theboral, J. (2019) · Journal of Reports in Pharmaceutical Sciences · doi:10.4103/jrptps.jrptps_54_18 · Cited by 1 · see citing works
Spontaneous MAOI hypertensive reaction, not likely armodafinil -tranylcypromine interaction
Feinberg, S. S. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.01.003 · Cited by 1 · see citing works
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1 · see citing works
Antidepressant Interactions of Ketamine and Glycogen Synthase Kinase-3 (GSK3) in Mice
Downey, K. (2015)
Early Development of Monoamine Oxidase Inhibitors
Klein, D. F., & Arden, P. C. (2014) · Psychiatric Annals · doi:10.3928/00485713-20141208-05
Stratagems of Nanotechnology Augmenting the Bioavailability and Therapeutic Efficacy of Traditional Medicine to Formulate Smart Herbal Drugs Combating
Margret, A. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-1043-7.ch011
In Reply: Spontaneous MAOI hypertensive reaction, not likely armodafinil - tranylcypromine interaction
Kinslow, C. J., & Miller, E. C. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.01.002
Monoamine Oxidase Inhibitors in Depressive Disorders
Meyer, J. H., Matveychuk, D., Holt, A., Santhirakumar, A., & Baker, G. B. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_98-1
Depressive Störungen
Laux, G. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_67-1
Stratagems of Nanotechnology Augmenting the Bioavailability and Therapeutic Efficacy of Traditional Medicine to Formulate Smart Herbal Drugs Combating
Margret, A. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-1798-6.ch073
Refs
(2017) · Wiley eBooks · doi:10.1002/9781119183839.refs

Monoamine Oxidase Inhibitors:A Modern Guide to an Unrequited Class of Antidepressants
Stahl, S. M., & Felker, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900016965 · Cited by 191 · see citing works
Self-citation
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
Chamberlain, S. R., & Baldwin, D. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00832-x · Cited by 50 · see citing works
Monoamine Oxidase Inhibitors in Depressive Disorders
Meyer, J. H., Matveychuk, D., Holt, A., Santhirakumar, A., & Baker, G. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_98 · Cited by 2 · see citing works
Monoamine Oxidase Inhibitors: A Clinical Colloquy
Tobe, E. H., Stewart, J. W., Staab, J. P., Zajecka, J., & Klein, D. F. (2014) · Psychiatric Annals · doi:10.3928/00485713-20141208-07 · Cited by 1 · see citing works
MAOI prescribing: separating misconceptions from reality
Molloy, A. (2023) · Prescriber · doi:10.1002/psb.2077 · Cited by 2 · see citing works

Authors: Grady, M. M., & Stahl, S. M.
Affiliations: Neuroscience Education Institute (US)
University of Cambridge (GB)
Corresponding author: Grady, Meghan M.
ORCID: Stahl, Stephen M.
Venue: CNS Spectrums
Publisher: Cambridge University Press (CUP)
Published: 2012-04-26
Volume: 17
Issue: 1
Pages: 2-10
ISSN: 1092-8529 (ISSN-L)
2165-6509
DOI: 10.1017/s109285291200003x
OpenAlex: W2074703267
Cited by: 51
References: 46
Citations by year: 2025: 1 · 2023: 2 · 2022: 6 · 2021: 8 · 2019: 3 · 2018: 3 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 3 · 2013: 5 · 2012: 1
FWCI: 3.29
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified)
Locations: CNS Spectrums (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords: monoamine oxidase inhibitors, depression, anxiety disorders, dietary restriction, drug interactions
MeSH terms: Anxiety Disorders, Depression, Drug Interactions, Humans, Monoamine Oxidase Inhibitors, Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Practical guide for prescribing MAOIs: debunking myths and removing barriers

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks